AN
Annexon, Inc.
ANNX · NASDAQ
$4.22 +1.32% (+$0.06)
1M -16.60%
Market Cap $691.4M
P/E Ratio -
Div. Yield -
ROE 106.15%
Bulios Fair Price
$3.62
14.2% downside
Current Price
$4.22
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ANNX is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
55 /100
Fair P/B 3.72x
EV/FFO N/A
P/S N/A
Growth
10 /100
Declining Book val. growth 2.90%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 106.15%
ROA 82.36%
Asset turnover 0.00x
Debt
100 /100
Low Current ratio 5.53x
Debt/Equity 0.13x
Net debt/EBITDA N/A
Stability
44 /100
Moderate EPS volatility 40.85%
Profitable years 0
Beta 1.22x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ANNX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Douglas E. Love
Employees
92
Headquarters
Brisbane
Upcoming events
09 NOV
Earnings
Upcoming earnings report